0.64
+0.0162(+2.58%)
Currency In USD
| Previous Close | 0.63 |
| Open | 0.67 |
| Day High | 0.67 |
| Day Low | 0.63 |
| 52-Week High | 2.95 |
| 52-Week Low | 0.34 |
| Volume | 529,868 |
| Average Volume | 7.87M |
| Market Cap | 26.77M |
| PE | -0.71 |
| EPS | -0.91 |
| Moving Average 50 Days | 0.61 |
| Moving Average 200 Days | 1.08 |
| Change | 0.02 |
If you invested $1000 in Cognition Therapeutics, Inc. (CGTX) since IPO date, it would be worth $50.45 as of February 05, 2025 at a share price of $0.644. Whereas If you bought $1000 worth of Cognition Therapeutics, Inc. (CGTX) shares 3 years ago, it would be worth $155.6 as of February 05, 2025 at a share price of $0.644.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC
GlobeNewswire Inc.
Jan 30, 2025 12:30 PM GMT
– Study demonstrated strong therapeutic responses across behavioral, functional, cognitive, and movement measures in patients with mild-to-moderate DLB – – Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI A-L), 52% on ac
Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences
GlobeNewswire Inc.
Jan 08, 2025 9:14 PM GMT
PURCHASE, N.Y., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that CEO Lisa Ricciardi will
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies
GlobeNewswire Inc.
Dec 18, 2024 12:22 PM GMT
- Improvements Across Measures of Behavior, Function, Cognition and Movement - - Expediting Plans to Advance CT1812 into Late-Stage Trials - - Full Results to be Presented at International Lewy Body Dementia Conference (ILBDC) - - Cognition Therapeut